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Abstract: Notably, α-conotoxins with carboxy-terminal (C-terminal) amidation are inhibitors of
the pentameric nicotinic acetylcholine receptors (nAChRs), which are therapeutic targets for
neurological diseases and disorders. The (α3)2(β2)3 nAChR subunit arrangement comprises a
pair of α3(+)β2(−) and β2(+)α3(−) interfaces, and a β2(+)β2(−) interface. The β2(+)β2(−) interface
has been suggested to have higher agonist affinity relative to the α3(+)β2(−) and β2(+)α3(−)
interfaces. Nevertheless, the interactions formed by these subunit interfaces with α-conotoxins are
not well understood. Therefore, in order to address this, we modelled the interactions between
α-conotoxin LsIA and the α3β2 subtype. The results suggest that the C-terminal carboxylation of LsIA
predominantly influenced the enhanced contacts of the conotoxin via residues P7, P14 and C17 on LsIA
at the α3(+)β2(−) and β2(+)α3(−) interfaces. However, this enhancement is subtle at the β2(+)β2(−)
site, which can compensate the augmented interactions by LsIA at α3(+)β2(−) and β2(+)α3(−)
binding sites. Therefore, the divergent interactions at the individual binding interface may account
for the minor changes in binding affinity to α3β2 subtype by C-terminal carboxylation of LsIA versus
its wild type, as shown in previous experimental results. Overall, these findings may facilitate
the development of new drug leads or subtype-selective probes.
Keywords: MD simulation; homology modelling; α-conotoxin; nicotinic acetylcholine receptor
interface; C-terminal amidation/carboxylation
1. Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels [1] that play
important roles in the mediating signalling transmission between neurons. Therefore, they are related
to numerous neurological disorders and diseases, such as Parkinson’s disease, Alzheimer’s disease,
dementia, schizophrenia and addiction [2–4]. These receptors exist as five subunit combinations
of α subunit (α2-10) only (homomeric α7 and α9 subtypes), or heteromeric combinations of α
and β (β2-4) subunits [5]. Each subunit comprises an N-terminal extracellular domain (ECD),
transmembrane domain (TMD) and an intracellular domain (ICD). The ECD is of particular importance
due to the presence of the canonical ligand-binding domain (LBD) at the interface of two adjacent
subunits [6,7]. It has been demonstrated that the α subunit ECD can facilitate the binding of agonists [8],
such as acetylcholine (ACh), at the LBD [1], resulting in the opening of the channel in the TMD.
Moreover, neuronal nAChRs are widely recognised as a target of α-conotoxins, such as LsIA, showing
high potency at α3β2 (IC50 10.3 nM) and α7 (IC50 10 nM) nAChR subtypes [9].
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The α3β2 subtype is expressed in the central and peripheral nervous systems, including
the cerebellum, spinal cord, and autonomic ganglion neurons [10,11]. Various stoichiometries
of the α3 and β2 subunits are known to exist, with the most common consisting of two α3 and three
β2 subunits, ((α3)2(β2)3) [12]. A recent study has suggested that the (α3)3(β2)2 stoichiometry may
also exist at the motoneuron-Renshaw cell synapse in the spinal cord [13]. In this stoichiometry, a
pair of β2(+)α3(−) and α3(+)β2(−) interfaces are commensurate with those constituting the (α3)2(β2)3
isoform. However, an α3(+)α3(−) interface in the former, (α3)3(β2)2, and a β2(+)β2(−) interface
in the latter, (α3)2(β2)3, cause the main structural differences between the α3β2 isoforms. Moreover,
the physiological and pharmacological properties of various nAChR isoforms may be affected by
the ratio of α to β subunits [14,15]. In addition, previous studies have also demonstrated the existence
of alternative stoichiometries of nAChRs, such as α4β2 ((α4)3(β2)2 and (α4)2(β2)3), α3β4 ((α3)3(β4)2
and (α3)2(β4)3) and α9α10 nAChR ((α9)3(α10)2 and (α9)2(α10)3) [14–19].
More importantly, a previous study by Boffi et al. has demonstrated that the different combinations
of subunit interfaces ofα9α10 nAChR showed distinct contributions ofα9 andα10, depending on which
serves as the (−) face to the binding of ACh [18]. Furthermore, the presence of α-conotoxins targeting
multiple interfaces of nAChRs has attracted attention for investigating the binding determinants of
the successful binding of the ligand at the receptors [15,19]. However, the role of the different interfaces
in the binding of LsIA to nAChRs remains unclear.
The combinations of an α subunit as the principal (+) face with one β subunit as complementary
(−) face that forms interfaces which are commonly accepted as the canonical region binding agonists
and antagonists. However, other different interfaces of α3β2 nAChR, namely β2(+)β2(−), β2(+)α3(−)
and α3(+)α3(−), may also contribute to the binding of ligands, such as ACh and α-conotoxin MII [20].
Further, the residues on β subunits have been suggested to be involved in the nAChR subtype
selectivity of α-conotoxins [21–23]. Other studies emphasized the important role of the β subunit
as a structural component, which serves as an accessory binding face for α subunits [18,21,24,25].
Therefore, it is intriguing to explore the role of the β2 subunit in interacting with novel α-conotoxins at
the different binding interfaces of the (α3)2(β2)3 nAChR isoform.
LsIA, isolated from the venom of Conus limpusi, is known to inhibit ratα3β2 nAChR with nanomolar
potency [9]. Similar to a range of α-conotoxins, native LsIA possesses an amidated C-terminus (C-T)
and two disulfide bridges contributed by four conserved cysteine residues (Cys1-Cys3, Cys2-Cys4).
These disulfide bridges also confer it with two structural loops consistent with the 4/7 subclass of
α-conotoxins, characterized by four amino acid residues in the first loop (loop 1 in the present study)
and seven residues in the second loop (loop 2) [21,26].
These structural characteristics may contribute to the high binding affinity of α-conotoxins to
nAChR subtypes. For example, LsIA has been shown to selectively inhibit human α7 and rat α3β2
nAChRs expressed in Xenopus laevis oocytes [9,27], whereas the LsIA[R10F] mutant preferentially binds
at human α3β4 nAChR [27]. Furthermore, the carboxy-terminal (C-terminal) amidation, together with
the sulfated tyrosine, are crucial for the activity of AnIB on α7, rather than α3β2 [28]. Similar to native
LsIA, most 4/7 α-conotoxins possess an amidated C-T in their natural form, namely α-conotoxins Vc1.1,
MII, GIC, AnIB, and TxIA. However, an amidated C-T does not exist in certain identified α-conotoxins,
such as GID and RgIA with a C-terminal carboxylate, that also bind at α3β2, α7 and α9α10 nAChRs
with high potency [26,29]. Notably, previous experimental results have shown that the C-terminal
carboxylation enhanced the binding affinity of LsIA at rat α3β2 nAChR three-fold, yet this modification
(C-terminal carboxylation of LsIA) resulted in a three-fold reduced affinity at human α7 nAChR.
In the present context, “C-terminal carboxylation” or “carboxylated C-terminus” refers to the presence of
a single COO- functional group that terminates the peptide backbone, compatible with the terminology
adopted by Inserra et al. [9] Although these differences are marginal, the investigation of the effects of
C-T of α-conotoxins on receptor interface interactions may nonetheless shed light on the possibilities
for improvements and design of α-conotoxins with high selectivity to individual nAChR subtypes [30].
Mar. Drugs 2020, 18, 349 3 of 23
The determined crystal structure of the acetylcholine binding protein (AChBP) has facilitated
the in silico studies of conotoxin-nAChR complexes. It has been shown that residues at the LBD of
the ECD of α3β2 and α7 share high sequence similarity with those of AChBP [31], which can provide
reliable homology models of nAChRs for molecular dynamics (MD) simulations and subsequent
computational analyses. Previous studies have employed the molecular modelling of nAChRs based on
the crystal structures of AChBP [31,32] and α1 nAChR subunit [33]. Moreover, numerous studies have
produced comparative models of conotoxins binding at nAChRs complex, built using the co-crystal
structures of Aplysia californica (Ac) AChBP with α-conotoxins TxIA[A10L], PnIA[A10L, D14K],
ImI and LvIA [34–40], respectively, as well as Lymnaea stagnalis (Ls) AChBP bound by α-cobratoxin [41]
and LsIA [27], respectively.
In the present study, we employed MD simulations to predict the determinants for
the differences in receptor interactions with amidated (LsIA) and carboxylated C-T (LsIA#) analogue
of LsIA at α3(+)β2(−), β2(+)α3(−) and β2(+)β2(−) interfaces (see Figure 1), which may help to
explain the differential inhibition of α3β2 by these two toxin isoforms. These results predict differences
in the structures, motions and intra-molecular contacts between LsIA# and LsIA, as to elucidate
the toxin-receptor interactions which are increased for LsIA# compared to LsIA at certain types of
interfaces, which may thereby be proposed to be key determinants for the increased inhibitory activity
of LsIA# at α3β2. The electrostatic property that affects the binding of LsIA# at α3β2 versus its
native type (LsIA) was also explored via Adaptive Poisson–Boltzmann Solver (APBS). Furthermore,
in addition to toxin-receptor contacts and their physical characteristics, we examined the structural
influences exerted on the receptor by the two LsIA isoforms and employed a molecular network
approach to compare the effects that each LsIA isoform may exert on contacts between adjacent nAChR
subunits at α3(+)β2(−) and β2(+)α3(−) interfaces. The consideration of inter-subunit contacts to
predict the potential bioactivity of α-conotoxins bound at specific nAChR interfaces is worthy of
further investigation.
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Figure 1. Binding mode of α-conotoxin LsIA at rat α3β2 nAChR. (A) Top view of LsIA anchored to
the receptor. The five subunits of theα3β2 and the LsIAs anchoring to five interfaces of the nicoti receptor
are labelled with their nomenclature names and the chai numbers used to identify subunits i this work.
The α3 and β2 subunits are represented by a blue and yellow colour, respectively, in NewCartoon form;
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in green, pink and red colours, respectively. (B) Side view of LsIA binding at the α3(+)β2(−)
interface. The homology model of the LsIA/α3β2 complex was constructed via homology modelling
(Modeller9v6 [42], and was further refined via molecular dynamics (MD) simulation (GROMACS
4.6.5 [43]). A detailed description of the methods is provided in the Materials and Methods section.
(C) The 3D structure of LsIA with 4 conserved cysteine residues shown in CPK form. The yellow
bonds represent the two disulfide bonds of the toxin. The amino acid sequence of LsIA is shown on
the right-hand side of the figure. The asterisk (*) denotes the C-terminal amidation.
2. Results
2.1. Stability and Flexibility of the LsIA-α3β2 Complexes
The root-mean-square deviation (RMSD) time series plots for the LsIA- and LsIA#-α3β2 complexes
are shown in Figure 2A–D, each time series of which was taken as an average over 28 independent
simulations. The fitting was performed on the Cα atoms of the entire receptor-ligand complex
and RMSD values were calculated for the respective individual chains, discussed below. These plots
demonstrate the stability of the backbone atoms of the protein complexes [44], all of which approach
a plateau in their respective RMSD plots by approximately 15 ns. The patterns of the RMSD plots
in the present study are qualitatively comparable to those of the RMSD results based on simulations of
other nAChRs-toxins models [45–47]. Despite the similarity of the RMSD plots of the α3β2 nAChR
subunits between LsIA and LsIA# bound forms, there are, however, some differences in the RMSD
behavior observed for both of the ligands. LsIA and LsIA# show an asymmetric pattern in their
RMSD plots, depending on the targeted α3β2 interfaces bound by the toxins, as shown by Figure 2C,D.
The figures demonstrate two distinct types of RMSD values. Chain G (bound at the β2(+)α3(−)
interface), chain I (β2(+)β2(−)) and chain J (β2(+)α3(−)) exhibited high values of RMSD (approaching
0.5 nm), whereas chain F (bound at α3(+)β2(−)) and H (α3(+)β2(−)) exhibited much lower RMSD
values (approaching 0.3 nm). The RMSD results indicate that LsIA, when bound at interfaces
involving β2(+) as the principal face, went through substantially greater structural drift from the initial
homology model compared to those bound at the α3(+) interfaces. This asymmetry may be because
the β2(+)α3(−), and β2(+)β2(−) interfaces are less preferable for the binding of LsIAs, compared with
the α3(+)β2(−) interfaces.
To obtain further insights into the regions of LsIA responsible for the interface-specific
differences in RMSD as described above, absolute root-mean-square fluctuation (RMSF) plots were
obtained for the LsIA- (Figure S1A,C) and LsIA#-α3β2 complexes (Figure S1B,D). To confirm that
the structural and dynamical properties of the LsIA-nAChR complexes were reasonably converged
within the simulation time frame, we plotted the sum of squared differences (SSD) at 3, 6, 9, 12, 15, 18,
21, 24 and 27 ns RMSFs for the average of the trajectories (Figure S2), as well as individual trajectories
(not shown). These plots indicate that 21 ns is sufficient for convergence, at least within the timescale
of the present simulations (Figure S2).
In the RMSF results for LsIA and LsIA# (Figure S1C,D), a high fluctuation in the N-terminus (N-T)
of LsIA was observed. For both LsIA and LsIA#, the values of the RMSF followed the same pattern
as the RMSD, with chains G, I and J (binding at β2(+) interfaces) exhibiting distinctly higher RMSF
compared to chains F and H (binding at α3(+) interfaces), particularly in the N-T and N15 regions.
Thus, the N-T of both LsIA and LsIA# appear to undergo far greater flexibility atβ2(+)α3(−) compared to
those bound at α3(+)β2(−) interfaces. The differences, mainly regarding the N-T of LsIAs, may suggest
important variations in toxin-receptor interactions, depending on the interface arrangement.
We also compared the differences in RMSF results between LsIA- and LsIA#-α3β2 complexes,
by subtracting the RMSF values of LsIA# bound α3β2 nAChR from those of the LsIA bound complex
(Figure 3A). Positive values represent enhanced flexibility of the backbone of the LsIA bound complex,
whereas lower flexibility (relative to LsIA#) is demonstrated by negative values. Only residues that
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show differences in RMSF values greater than 0.5 (Å) were included, as this value has been used as a
cut-off point in previous MD simulation studies comparing similar proteins in different states [48,49].Mar. Drugs 2020, 18, x 5 of 24 
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Figure 2. Root-mean-square deviation (RMSD) (Mean ± SD) plots of LsIA and its carboxylated
analogue (LsIA#) binding at α3β2 pentameric nicotinic acetylcholine receptors (nAChR). (A) RMSD
plots of LsIA bound α3β2. (B) RMSD plots of LsIA# bound α3β2. ‘Amid’ represents the amidated
LsIA bound to α3β2 nAChR, whereas ‘Carb’ represents the carboxylated LsIA (LsIA#) bound α3β2
nAChR subunits. RMSD plots of (C) LsIA and (D) LsIA# upon anchored to the nAChR.
For α3β2 (Figure 3A), there is an increased RMSF value in some regions, including Cys-loop
and C-loop of the LsIA-bound α3 subunit versus the LsIA# complex, illustrating the enhanced flexibility
in this region. Greater C-loop flexibility may infer a lower capacity for LsIA to lock the ligand-binding
site in an open-loop, inhibited conformation, or may be indicative of weaker receptor-toxin interactions
for LsIA l ading to higher flexibil ty. In contrast, for the β2 subunit, th opposite result was observed,
showing that the rigidity of these regions is higher for the LsIA bound subunit compared to the LsIA#.
In contrast to th observation regarding the C-loop of the α3 subunit, the enhanced rigidity of the β2
subunit bound by LsIA, may suggest that LsIA has less effect on suppressing Cys-loop and C-loop
movements at α3(+) rather than β2(+) interfaces. However, the increased flexibility of residues
in the Cys-loop and C-loop of the α3 subunit was not significant at the 5% level, except for the two
residues, α3-Y215 (P-value 0.031) and α3-C217 (p-value 0.016), which showed statistically significant
differences from the α3 subunit of α3β2 nAChR bound by LsIA#. Further, the α3-Y215 residue played
an important role in ACh binding at α3(+)β2(−) interfaces, by forming aromatic interactions with
the neurotransmitter [20].
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Figure 3. Differences between RMSF plots of LsIA and LsIA# binding atα3β2 nAChR. (A) Averaged
diff in RMSF plot of α3β2 subunits bound by LsIA. The ’Amid’ label the positive side of
the y-axis represents the LsIA bound subunits to higher flexibility versus the LsIA# bound form,
whereas the ’Carb’ label on the negative side of the axis shows that the LsIA# bound form gains higher
flexibility over the LsIA bound subunit. (B) Diff in RMSF for ligands anchoring to the nicotinic receptor
interfaces. The differences of RMSF between LsIA and LsIA# (The RMSF value of LsIA# was subtracted
by that of LsIA) are demonstrated, with different bar colours for the LsIA binding at different interfaces.
The diff in RMSF of LsIA binding at α3(+)β2(−), β2(+)α3(−), and β2(+)β2(−) interfaces are shown
with beige, yellow and green, colours respectively, whilst the averaged diff in RMSF of LsIA is shown
in pink colour. The statistical significance of changes in the RMSF of α3 and β2 subunits bound by
LsIA/LsIA# and the individual residues of LsIA/LsIA# (binding at different interfaces), was calculated
over 28 individual seeds (* p < 0.05; ** p < 0.001).
For LsIA (Figure 3B), the differences in RMSF values are shown for the different interfaces of
the α3β2 nAChR bound by the toxins. At α3(+)β2(−) interfaces, LsIA# was less flexible than LsIA
at most positions, especially for the residues, N13, P14, N15, I16 of loop 2 and the C-T (beige bars,
Figure 3B). This suggests that at α3(+)β2(−), LsIA# may form a higher number of intermolecular
contacts with the r ceptor, or may form internal intr -molecular contacts, whi h can r sult in its
signific tly greater rigidity. At the β2(+)α3(−) interfaces, LsIA# was, however, less flexible than LsIA
in only loop 1, whereas LsIA# exhibited similar flexibility to LsIA in loop 2 (yellow bars, Figure 3B),
in contrast to the observed RMSF behavior for α3(+)β2(−) above. Finally, at the β2(+)β2(−) interface, a
different RMSF behavior was observed; aside from LsIA-G1 and S2, LsIA# exhibited higher flexibility
for both loops 1 and 2 compared to LsIA (green bars, Figure 3B). Thus, at both mixed subunit interfaces,
the structure of LsIA# was generally more rigid than LsIA, but at β2(+)β2(−), LsIA# was only more
rigid at residues 1 and 2, but more flexible elsewhere in both loops 1 and 2. Therefore, we propose that
the enhanced rigidity of LsIA# compared to LsIA at α3(+)β2(−) interfaces is qualitatively consistent
with the expectation that LsIA# should have greater toxin-receptor contacts than LsIA (and therefore
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less mobile), given the known higher potency of LsIA# at α3β2. There is also an indication that
at the β2(+)α3(−) interfaces, LsIA# might be marginally more rigid than LsIA, although caution
must be exercised in this interpretation, due to lack of statistical significance at the 5% level for
the results at this type of interfaces. It is plausible that considering both these mixed interfaces may
help elucidate the toxin’s differential potency. However, the same cannot be said for β2(+)β2(−),
for which there was generally higher flexibility for LsIA#, suggesting less toxin-receptor contacts. Thus,
the consideration of β2(+)β2(−) is less likely to have a predictive value, and in subsequent sections,
we focused our discussion mainly on α3(+)β2(−) and β2(+)α3(−) interfaces, with the majority of
the β2(+)β2(−) results provided in Supplementary Materials. To elucidate the determinants affecting
the possible differences at α3β2 interfaces’ binding potency by LsIA and its analogue, we further
investigated the basis for the distinctions in RMSF behavior between LsIA and LsIA# at the α3(+)β2(−)
and β2(+)α3(−) interfaces, by examining specific intra- and inter-molecular contacts between LsIA
and the α3β2 receptor discussed below.
2.2. LsIA and LsIA# Toxin-Receptor Contacts
The total number of contacts for each residue of LsIA formed with α3β2 is depicted in Figure 4A,
whereas Figure 4B,C and Figure S3 show the important pairwise interactions influencing receptor
interactions by the LsIAs anchored to theα3(+)β2(−) (Figure 4B),β2(+)α3(−) (Figure 4C) andβ2(+)β2(−)
(Figure S3) interfaces.
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Overall, the LsIA# with α3β2 nAChR complex had higher inter-residue contacts between
the ligand and the receptor versus the LsIA bound complex, as can be seen in Figure 4A. The total
number of receptor interactions made by LsIA was mainly contributed by P7 on loop 1, and with
R10 and V11 on loop 2 for both LsIA and LsIA#. The higher toxin-receptor contacts may partially
explain the higher rigidity of LsIA# at both α3(+)β2(−) and β2(+)α3(−) interfaces, compared with
the LsIA bound complex.
In terms of the specific determinants affecting the total receptor interactions by LsIAs, pairwise
interactions between the receptor and the LsIAs were further investigated via gmx mindist with cutoff
4.5 Å. To make the differences in per-residue contacts between LsIA and LsIA# at the α3(+)β2(−)
interfaces clear, the number of individual pairwise contacts of LsIA# was subtracted by that of
LsIA. Thus, a negative value represents relatively higher LsIA# contacts, whereas the positive value
shows higher contacts for LsIA with the corresponding residues on α3β2 nAChR, which is indicated
within the bars for each LsIA residue. The absolute value of 4 for the differences in the number of contacts
for coupled residues was selected as a threshold for including the potentially important pairwise
contacts affecting the receptor interactions. Additionally, for ease of interpretation, pairwise interactions
were excluded if the original number of contacts, between LsIA and LsIA# bound complexes, was less
than 15, indicating a low level of contacts formed by the coupled residues. The statistical significance
was evaluated for the selected pairwise interactions over 28 individual simulations. It is shown that
P7, P14 and C17 formed the most significant variations in several contacts between LsIA and LsIA#
binding at both α3(+)β2(−) and β2(+)α3(−) interfaces (Figure 4B,C), and fewer differences occurred at
the β2(+)β2(−) interfaces (Figure S3). The interactions involving each of the above LsIA residues at
the α3(+)β2(−) and β2(+)α3(−) interfaces are discussed in turn in the following sections.
2.3. Important Pairwise Interactions of LsIA with Residues at α3(+)β2(−) Interfaces
The increased contacts between LsIA#-C17 and β2(−)-K187 likely exerted the greatest impact on
improved binding affinity of LsIA# versus LsIA at α3(+)β2(−) interfaces, together with P7 and P14
forming hydrophobic interactions with corresponding aromatic and hydrophobic residues, F143,
L145 and W81, on the β2 subunit. The dominant enhanced contacts occurred between LsIA#-C17
and β2(−)-K187 via salt-bridge/hydrogen bonds interactions, which were absent in the LsIA/α3β2
complex (Figure 5 and Figure S4). Additionally, the proximity between P7 and β2(−)-W81
and β2(−)-L145 and the enhanced pairwise contacts between P14 and β2(−)-F143 (Figures 5 and 6)
contributed to the augmented hydrophobic interactions in LsIA# versus the LsIA bound form.
Furthermore, the salt-bridge interaction between C17 and R10 of LsIA# (Figure S5) directly
facilitated the LsIA#-R10 contact with β2(−)-L145, via forming van der Waals interactions (Figure 6),
by placing the toxin in a favorable conformation for such interaction. Although the interactions
formed by LsIA#-R10 and β2(−)-W81 were reduced against the LsIA bound form, the distance between
the coupled residues was relatively large in the latter complex. Thus, the carboxylation of LsIA
probably causes a switch in the favorable interaction of R10 with β2(−)-W81 (for LsIA) to β2(−)-L145
(for LsIA#). Nevertheless, as the van der Waals interaction between R10 and β2(−)-L145 was relatively
weak, this “switch” may only result in a slightly overall increased number of contacts between the key
residue R10 and the receptor at the α3(+)β2(−) interfaces by LsIA#. Consequently, the ability to form
a salt bridge/hydrogen bond between the C-T and β2(−)-K187 is likely to be a key factor explaining
the higher affinity of LsIA# compared to that of the amidated form LsIA at α3(+)β2(−) interfaces.
This interaction may also play a critical role in helping produce an overall higher number of contacts
between α3β2 and LsIA# compared to LsIA bound form, by drawing the toxin closer to the (−) face of
the receptor, indirectly stimulating the significantly augmented contacts at other residues, such as R10
and P14, as discussed above.
However, contrary to the β2 subunit at α3(+)β2(−) interfaces, the changes in receptor contacts
at α3(+), between LsIA and LsIA# bound interfaces were minor, apart from significantly enhanced
contact between α3(+)-Y215 and LsIA#-C3 versus the LsIA bound form (Figure S6). Other interactions,
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such as N6-(+)Y22, P7-(+)W174 and G2-(+)Y215 only slightly affected the binding affinity of the toxin due
to C-terminal carboxylation (Figure S7).
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Figure 5. Important interactions for by LsIA-P14 and C17 with he recept r residues on
the comple entary (−) face at t e α3(+)β2(−) interface. Binding mode of LsIA (transparent green)
(A) and LsIA# (transparent orange) (B) at the (−) face with the pairwise interactions which may
substantially affect the binding affinity. The key residues involved in pairwise interactions on LsIAs are
shown in CPK form, whereas the correspondi g residues on the receptor are depicted with the Licorice
form (a drawing format of graphic presen ation vi ual lecular dyna ics (VMD)). Th red dashed
line represents the contacts that are much stronger in this form of LsIA/α3β2 complex. Snapshots were
chosen by visual inspection for illustrative purposes. (C) The distance (Å) between the coupled residues
of bound forms. Moreover, 32a represents the LsIA bound type, whereas 32c denotes the LsIA# bound
complex. The coloured dashed lines represent the median distance of the pairwise residue. The y-axis
shows the probability density function of the distance between the coupled residues, which is involved
in all the distance (Å) plots in this study.
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interactions dramatically influences the binding affinity. (C) The distance (Å) between the coupled
residues of bound forms that affect the changes in α3(+)β2(−) interface interactions by the toxin.
2.4. Important Pairwise Interactions of LsIA with Residues at β2(+)α3(−) Interfaces
Carboxylation of the C-T of LsIA also results in markedly enhanced pairwise interactions with
residues on the α3(−) subunit of β2(+)α3(−) interfaces, such as and C17-(−)K82 and V11-(−)L134,
via salt-bridge/hydrogen bond and hydrophobic interactions, respectively (Figures 4C and 7).
The increased number of receptor contacts for LsIA# was even more pronounced at β2(+)α3(−)
than at the α3(+)β2(−) interfaces, except for the weakened contacts between LsIA#-P7 and α3(−)W80
versus the LsIA bound form. This is shown in Figure 4C, in which LsIA#, occupying the β2(+)α3(−)
sites, had a greater relative number of contacts at the key residues demonstrated previously, such as P7,
A8, R10, V11, P14 and C17 (with contact number differences of up to ~−30), compared to at α3(+)β2(−)
(with contact number differences of only up to ~−15). This suggests that the carboxylation of C-T
may cause a greater enhancement in binding affinity at β2(+)α3(−) compared to that at α3(+)β2(−)
binding sites, such that the interactions at this interface may also be used to predict LsIA activity.
Nevertheless, it should be noted that the changes in the number of contacts with statistical significance
were commensurate with those at α3(+)β2(−), except for the additional substantially enhanced van
der Waals contacts between R10 and I144 at β2(+)α3(−) bound by LsIA#.
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(rotated ~180◦ of the y-axis) (A,C) and LsIA# (transparent grey) (rotated ~ 180◦ of the y-axis) (B,D)
at the (−) face with the pairwise interactions which may substantially affect the binding affinity. For
better visualization, the unrelated residues in the figures are shown in transparent colour and labelled
with smaller size font. (E) The distance (Å) between the coupled residues of bound forms.
Similar to the α3(+)β2(−) interfaces, the C-terminal carboxylation may directly enhance
the interactions established by LsIA#-C17 with a lysine residue at the (−) face, namely α3(−)-K82.
Figures 4C and 7 illustrate that LsIA# had greater contacts between the negatively charged C-T
and α3(−)-K82 on β2-sheet of α3 subunit, which was also confirmed in the ligand interaction 2D
diagram (Figure S4B,E). However, it appears that the proximity between α3(−)-K82 and LsIA#-C17
may not facilitate enhanced interactions by R10 and α3(−)-W80. At both β2(+)α3(−) and α3(+)β2(−)
binding sites, the intramolecular interactions of R10-C17 in LsIA# may only interfere with the enhanced
interactions between LsIA# and α3(−)-W80 as well as β2(−)-W81, via mainly favoring the binding of
LsIA over LsIA# to the binding interfaces. Further, few variations of interactions occurred at β2(+)
subunit (Figure S8), resembling the α3(+)β2(−) interfaces.
In contrast, at β2(+)α3(−), R10 made more increased contacts with three residues for LsIA# relative
to LsIA, namely, α3(−)-I144, K82 and W80 (Figure 4). Particularly, the α3(−)-I144 formed substantially
enhanced contacts with LsIA#-R10, shown in Figure 7. However, at α3(+)β2(−), LsIA#-R10 had
higher contacts only with two residues, β2(−)-L145 and β2(−)-F143. Apart from this, LsIA#-P14 made
enhanced contacts with two receptor residues, α3(−)-K82 and T142 (Figure 7), relative to LsIA; this is
in contrast to the α3(+)β2(−) interfaces, for which LsIA#-P14 established markedly enhanced contacts
with a single residue, β2(−)-F143.
2.5. Understanding Changes in Electrostatic Potential by C-terminal Carboxylation of LsIA at α3(+)β2(−)
and β2(−)α3(+) Interfaces
In order to understand the effects of C-terminal carboxylation on the electrostatic properties of
LsIA and α3β2 nAChR, which may shed further light on the differences in LsIA and LsIA# activities, we
conducted an adaptive Poisson–Boltzmann solver (APBS) [50] analysis on LsIAs binding at α3(+)β2(−)
and β2(+)α3(−) via PyMOL APBS plugin [51] (APBS Tools 2.1). PyMOL with an APBS plugin facilitates
the visualization of electrostatic potential 3D surface molecules after calculation [52]. The Protein Data
Bank format file of molecules was pre-processed via pdb2pqr [53] software for assigning parameters of
the atoms, such as radius and charge, from various force fields [54].
The results demonstrated that the surface of C-terminal residues, C17 and P14, of LsIA obtain a
larger negatively charged surface versus that of LsIA# (Figure 8A). Additionally, the pocket formed
by β2(−)-F143, L145 and K187 on the β2 subunit of α3(+)β2(−) interfaces bound by LsIA were
predominantly negatively charged. However, a relatively neutral/positively charged cavity formed
by the corresponding residues on LsIA# bound interfaces was identified (Figure 8B). Therefore,
electrostatic repulsion between LsIA and α3(+)β2(−) interfaces may substantially intervene in the α3β2
nAChR binding affinity versus the LsIA# bound form. For β2(+)α3(−), the surface of the binding
cavity around α3(−)-L134 and K82 was dominated by neutral/positive charge when bound by LsIA#
versus the LsIA anchoring form (Figure 8C,D), which resembled the α3(+)β2(−) binding site. We also
observed an electrostatic interaction between α3(−)-K82 with LsIA#-R10 (Figure 8D),which may confer
a stronger repulsion between them. This type of charge-charge interactions was also determined
in previous studies, such as the interactions between α-conotoxin ImI-R11 and R148 and H146 on
LBD of Ls-AChBP [55], as well as LsIA-R10-K57 on the β4(−) subunit of α3β4 nAChR [27]. Both of
the electrostatic repulsions interactions are associated with the low binding affinity of ImI and LsIA at
these nAChRs, compared to other nAChR subtypes, such as α7 and α3β2 nAChRs.
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shown in PyMOL [56]. (A,C) LsIA binds at α3(+)β2(−) and β2(+)α3(−) interfaces, respectively.
(B,D) LsIA# binds at α3(+)β2(−) and β2(+)α3(−) interfaces of α3β2 nAChR. The electrostatic potential
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2.6. Inter-subunit Contacts at the α3(+)β2(−) and β2(+)α3(−) Interfaces
To determine the effects of inter-subunit contacts between residues on the binding interfaces,
we employed a network interaction analysis implemented in the software Cytoscape [57]. Differences
in inter-subunit contacts help reveal changes in the relative orientations of the subunits at toxin-bound
interfaces, which may be related to the capacity of the toxins to inhibit nAChR function [36,58–60].
At the α3(+)β2(−) interfaces, α3(+)-S152 (on the Cys-loop) formed close hydrogen bond
interactions with β2(−)-Q65 and β2(+)-A63, when bound with LsIA. These interactions were disrupted
when LsIA# is bound, which is associated with an increased distance between the interfaces in the lower
region (Figure 9A). In contrast, the van der Waals interactions formed by α3(+)-G123 and β2(−)-S129
were increased for LsIA# relative to LsIA, and is associated with a reduction in the distances between
the interfaces in the middle part of the LsIA#-bound interfaces.
There was also a relative increase in distance betweenα3(+)-W174 andβ2(−)-W81 for LsIA#-bound
α3(+)β2(−) interfaces compared to LsIA. This corresponds to a shorter distance between these residues
for LsIA-bound interfaces. The closeness between α3(+)W174 (on the β7/β8 loop) and β2(−)W81
(which lies on the β2 strand) when LsIA bound (Figure 9A and Figure S10), may have implications
for how LsIA interacts with α3β2 interfaces. In particular, these contacts might lead to an upward
shifting of (−)W81, which benefits the enhanced interactions between β2(−)W81 and LsIA-R10, and yet
indirectly affect the changes in contacts in other important pairwise interactions. For example, LsIA-P7
and P14 formed reduced hydrophobic interactions with β2(−)-W81, L145 and F143 (on the β5 strand),
associated with minor decreased contacts between the LsIA-R10 and β2(−)-L145, versus the LsIA#
bound complex.
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Figure 9. Inter-subunit interactions between the principal and the accessory face of α3β2 nAChR
interfaces bound by LsIA. Contacts at α3(+)β2(−) (A) and β2(+)α3(−) (B) interfaces bound by LsIA
and LsIA#. The region where differences in interactions occur due to anchoring of LsIA and LsIA#
is shown with green and pink background colour, respectively. The pairwise interactions showing
significant divergence in both forms are shown in bold form.
Overall, at α3(+)β2(−) interfaces, LsIA# binding caused greater separation between the α3(+)
and β2(−) subunits compared to LsIA at specific regions, including α3(+)S152 on the Cys-loop with β2
(−)Q65 and (−)A63, respectively, and α3(+)-W174 with β2(−)-W81, while reducing the separation at
(+)G123 and (−)S129.
At the β2(+)α3(−) interfaces, we identified relatively strong hydrophobic interactions between
β2(+)-W175 (also on the β7/β8 loop) and α3(−)-I144 (on β5 strand) for the LsIA#-bound form (Figure 9B
and Figure S10), which may influence the differentiation between LsIA and LsIA# bound complex on
β2(+)α3(−) interfaces, demonstrating greater contacts for the LsIA# and residues on the β7/β8 loop
and (−)I144 by R10. In summary, LsIA# binding caused greater contacts between the subunits, drawing
them closer, especially via the β2(+)-W175 and α3(−)-I144 residues. This is consistent with the contact
difference plots (Figure 4), showing that at the β2(+)α3(−) interfaces, the binding of LsIA# resulted in a
much greater increase in contacts relative to LsIA, when compared to that at the α3(+)β2(−). Part of
this may be because LsIA# less effectively draws together the β2(+) and α3(−) subunits, which favors
the interactions with the toxin relative to LsIA.
3. Discussion
3.1. Different Combinations of the Interfaces in Rat α3β2 may Affect the Distinct Stability and Flexibility of
the Receptor and LsIA
Simulations revealed differences in the overall dynamics and structure of the toxin-receptor
complex when bound with either LsIA# or LsIA. In addition, there are also variations at the α3(+)β2(−)
compared to β2(+)α3(−) interfaces.
The examination of the RMSD shows interface-dependent differences. For the ligands (LsIA
and LsIA#), a distinct pattern of the toxin RMSD values is observed at β2(+)α3(−) (chains G and J)
and β2(+)β2(−) (chain I) interfaces, different from those binding at α3(+)β2(−) interfaces (chains F
and H), for both LsIA and LsIA# bound complexes (Figure 2C,D). Although a negative charge at
the C-terminal carboxylate of LsIA# may affect the conformation of the ligand as well, this asymmetry
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pattern arising at both LslA and LsIA# RMSD plots may clarify doubt about the conformational
changes induced by C-terminal carboxylation. These differences in RMSD suggest that both LsIA
and LsIA# may adopt different conformations at the α3(+)β2(−) versus β2(+)α3(−) and β2(+)β2(−)
interfaces, particularly at the N-T of the ligand for both LsIA and LsIA#. Thus, these results may
highlight the potential importance of nAChR interfaces in influencing the preferred conformations of
bound conotoxins.
To explore the molecular basis of the differentiation between LsIA# and LsIA, as well as between
the interfaces, the differences in RMSF value are also compared in this study, as shown in Figure 3A,B,
indicating the different flexibility of the α3β2, and the toxins, for the LsIA and LsIA#-α3β2 complexes.
The Cys-loop and C-loop of LsIA bound α3 subunit in the LsIA bound complex showed higher
flexibility compared to the LsIA# bound subunit (Figure 3A). This appears consistent with the reduced
rigidity of Cys-loop observed in several computational studies on α7 nAChR bound by antagonists
versus the apo type [45,46]. However, to avoid the over-interpretation of the RMSF data, we also
calculated the statistical significance of the RMSF differences between LsIA and LsIA# bound forms.
As a result, only two residues, Y215 and C217 on the C-loop of α3 subunit, showed significantly
enhanced rigidity upon binding by LsIA#.
For LsIA, the averaged differences in RMSF resemble those in LsIA bound at the human
α7 nAChR, illustrating a more rigid structure of the loop 2 in the ligand, and relatively flexible
backbone characterizing the loop 1 for LsIA# compared to LsIA. At both mixed subunit, α3(+)β2(−)
and β2(+)α3(−) interfaces, the structure of the loop 2 of LsIA# is generally more rigid than LsIA.
However, this observation (increased rigidity of loop 2 of LsIA#) is only critical at α3(+)β2(−) binding
sites. The remarkably enhanced rigidity of LsIA# compared to LsIA at α3(+)β2(−) interfaces is
qualitatively consistent with the expectation that LsIA# should have greater toxin-receptor contacts
(and therefore less mobile) than LsIA does, given the known higher potency of LsIA# at α3β2. It is
plausible that both of the mixed interfaces may need to be studied, particularly for the LsIA/α3(+)β2(−)
interfaces, which show significant rigidity differences between the LsIA and LsIA# at loop 2
and C-T. We explained the toxin’s differential potency in regard to their interactions with α3β2
in the following sections.
3.2. C-terminal Carboxylation of LsIA Marginally Enhanced Overall α3β2 nAChR Contacts Versus LsIA
Overall, the total number of contacts formed by the LsIA# with the α3β2 nAChR marginally
surpasses that of the LsIA (Figure 4A), which is consistent with the experimental study, concluding that
the potency of LsIA at α3β2 is enhanced three-fold via the C-terminal carboxylation of the LsIA [9],
as mentioned previously. In particular, LsIA#-C17 and P14 are two key residues which were identified
to form remarkably greater contacts with the receptor compared to LsIA. The enhanced contacts of
the LsIA# may be induced by the potential intra-molecular salt bridges or hydrogen bonds established
by the C-T (C17) and the R10 (Figure S5), which enhanced the rigidity of the residues in loop2, namely
V11, N13, P14, N15, I16 and C-T, rather than R10. This increased rigidity was also suggested in a
previous experimental study using an electrophysiological recording approach and predicted in our
computational study on LsIA/α7 nAChR systems [9,61]. Therefore, the C-terminal carboxylation not
only directly results in the enhanced receptor interactions by the C-T, but also improves the receptor
interactions by P14 of the LsIA#.
However, the relatively reduced receptor contacts at C3, A8, C9, N12 and I16 may partly offset
this slightly increased number of α3β2 interactions by LsIA# over the LsIA. Furthermore, among all
the residues of LsIA/LsIA# strongly interacting withα3β2 nAChR, C3, P7, R10, N12 and P14 show larger
variations in terms of the number of receptor contacts over five binding interfaces. This may suggest
that the interactions by the LsIA/LsIA# with an individual type of α3β2 interfaces, namely α3(+)β2(−),
β2(+)α3(−) and β2(+)β2(−), may differ from each other. Therefore, the identification of the statistically
significant changes in receptor contacts by individual residues was implemented for the prediction of
the key residues involved in enhanced α3β2 interactions by LsIA# versus LsIA, among all α3β2 binding
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interfaces. It is also of interest to explore if different α3β2 nAChR interfaces may affect the slightly
reduced binding affinity of LsIA versus its C-terminal carboxylation form.
3.3. C-Terminal Carboxylation of LsIA Mainly Enhances the Contacts with Residues on the Complementary
Subunit of both α3(+)β2(−) and β2(+)α3(−) Interfaces
The key important pairwise interactions include that formed by C17 and β2(−)-K187 via forming
hydrogen bonds/salt bridge, which is reinforced in the LsIA# bound complex, together with a
dramatically enhanced hydrophobic interaction between P14 and β2(−)-F143 on α3(+)β2(−) interfaces
of α3β2 nAChR versus the LsIA-bound complex (Figure 5). The geometry of LsIA#-C17 confers
strong hydrogen bonds or salt-bridges established by the carboxyl group of C17 with β2(−)-K187.
In our previous study, similar hydrogen bonds between LsIA#-C17 and (−)Q79 of human α7 nAChR
were determined [61]. Interestingly, salt bridges/hydrogen bonds formed by other α-conotoxins
and the receptor are involved in anchoring the inhibitors to nAChRs. For example, β2(−)-K187
on α3(+)β2(−) interfaces of α3β2 nAChR was implicated in charge-charge interactions with E11 of
the α-conotoxin MII [20], whereas human β2(−)-D171 (D196 as numbered from first Met) forms
relatively strong contacts with G1 of α-conotoxin RegIIA via salt-bridge [62], when the identical
aspartic acid residue is situated in position 195 of the rat β2 subunit. Further, the proximity between
LsIA#-C3 and α3(+)-Y215 confers substantially enhanced hydrogen bond contacts by LsIA# with α3β2
nAChR (Figure S6). The (+)Y215 of α3 subunit has been suggested to be important for the binding of
ACh to α3(+)β2(−) binding sites via aromatic interactions [20]. This is also the only residue on the (+)
face at both α3(+)β2(−) and β2(+)α3(−) interfaces showing markedly different effects on the binding
between LsIA and LsIA#.
At the (−) subunit on the α3(+)β2(−) interfaces of α3β2 nAChR, other important differential
interactions involve those formed by P7 and P14 with aromatic and hydrophobic residues, β2(−)-W81,
F143 and L145, via hydrophobic interactions, which are significantly enhanced in the LsIA# bound
complex versus the LsIA (Figures 5 and 6). The hydrophobic interactions between residues on
α-conotoxins and aromatic residues of nAChRs were also identified in a previous study. For instance,
a hydrophobic interaction is formed between L15 of LtIA with F119 (F143 from first Met) on the rat β2
subunit of α3β2 nAChR [32]. This interaction favors the selectivity of LtIA to α3β2 nAChR versus
the α3β4 subtype.
On the contrary, the contacts formed by LsIA#-R10 with β2(−)-W81 and L145 slightly affect
the different receptor interactions between LsIA and LsIA#, by compensating the changes in contacts
between each other. More importantly, the stacking interactions (cation-π and π−π interactions)
by R10 were not observed for either LsIA or LsIA# bound interfaces. This finding differs from
the previous studies, illustrating the important role of stacking contacts in α-conotoxins anchored
to nAChRs. The stacking interactions formed by the antagonists with aromatic residues on nAChRs
were determined in numerous previous studies on α-conotoxins and ACh binding at nAChRs [6,30,35].
The proximity of R7 ofα-conotoxin ImI with the aromatic residue, namely Y195, W149 and Y92 on the (+)
face of the human α7 nAChR, may form cation-π interactions for stabilizing the ligand and receptor
complex [1,31]. Similar π−π interactions were found between α-conotoxin MII-H9 and H12 and (−)F119
at α3(+)β2(−) interface and the (−)W55 at β2(+)α3(−) interfaces of rat α3β2 nAChR by Sambasivarao
and colleagues [20]. Other cation-π and π−π interactions were determined in the F9 of AuIB with W59
and K61 onβ4(−) subunit ofα3β4, and LsIA-R10 with (−)W77 of humanα7 nAChR, respectively [36,61].
The residues on position 5 of α-conotoxins may contribute to the potency of toxins at nAChRs via
establishing polar interactions with negatively charged residues. In this study, the persistent hydrogen
bond interactions between S5 and β2(−)-D195 stabilized the toxins bound to α3β2 nAChR in both
LsIA and LsIA# complexes (Figure S4A,D). It has been suggested that this aspartic acid on rat β2
subunit establishes salt-bridge interactions with the R5 of LtIA, associated with S168 [32], rendering
the toxin with a shallow binding position versus other α-conotoxins targeting nAChRs. In addition,
the aspartic acids in position 197 and 195 at the α3(+) subunit of rat α3β2 and Ac-AChBP, respectively,
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also play an important role in the increased sensitivity of TxIA[A10L] to the receptors via electrostatic
interactions with R5 of the toxin [34]. Taken together, our results support the important role of
the charged residues on the F-loop of the β2 subunit of α3β2 nAChR in selectivity by α-conotoxins.
At β2(+)α3(−) interfaces, for LsIA#, a salt bridge/hydrogen bond interaction exists between
α3(−)-K82 and C17, together with other major hydrophobic interactions, such as LsIA#-V11
and α3(−)-L134 (Figure 7 and Figure S4), for increasing the binding affinity by the toxin. Similarly
to α3(+)β2(−) interfaces, the LsIA#-C17 formed a substantially enhanced interaction with α3(−)-K82
via electrostatic interactions (Figure 8). The hydrogen bond/salt bridge interaction exerts the most
critical impact on enhancing the binding affinity of LsIA# at α3β2 nAChR, associated with another
substantially increased pairwise contacts between LsIA-V11# and α3(−)-L134 via hydrophobic
interactions. The α3(−)-L134 residue is also a homologous residue at position 107 of the human
α7 subunit, in which the (−)L107 of α7 subunits forms hydrophobic interactions with ImI-W10 [31].
We also observed a proximal distance between LsIA#-R10 and α3(−)-I144 for forming van der Waals
interactions versus the LsIA bound form, with a resemblance to the enhanced van der Waals interactions
between LsIA#-R10 and β2(−)-L145 at α3(+)β2(−). LsIA# binding generally causes a higher association
between the subunits at the Cys-loop regions compared to LsIA at α3(+)β2(−) (Figure 9). At β2(+)α3(−)
interfaces, the binding of LsIA# binding causes slightly reinforced contacts between the subunits,
drawing them closer together, except for the β2(+)-W175 and α3(−)-I144 residues. This is consistent
with the contact difference plots (Figure 4), which show that at both interfaces, LsIA# shows a higher
number of contacts with α3β2 compared to LsIA. This may, in part, be due to LsIA# being more able to
effectively draw together the subunits. Additionally, α3(−)-I144 is also homologous with (−)L141 on α7
subunit of human α7 nAChR, which was determined to form an enhanced interaction with LsIA-R10
of LsIA versus the carboxylated analogue [61]. In summary, the hydrophobic residues, isoleucine
and leucine, at this homologous position, may contribute to the enhanced interactions by LsIA# at α7
and α3β2 nAChRs versus the wild type.
Nevertheless, the interactions between LsIA#-P7 and α3(−)-W80 are reduced, in contrast to
the binding of LsIA via establishing hydrophobic interactions with the pyrrolidine ring of P7.
Thus, the role of α3(−)-W80 and β2(−)-W81 putatively favors the binding of LsIA compared with LsIA#
at both α3β2 interfaces via hydrophobic or van der Waals interactions, despite enhanced interactions
between P7 and β2(−)-W81.
The electrostatic repulsion may undermine the contacts formed by LsIAs-R10 with aromatic
residues at the β2(+)α3(−) interface via stacking interactions. The loss of aromatic/stacking interactions
between LsIAs-R10 and corresponding aromatic residues probably bears a close resemblance to that
on α3(+)β2(−) interfaces. Neither was a significant and strong change in such interactions by R10
observed. The closer distance between LsIA#-R10 and C17 via intramolecular salt bridge interaction
may induce the electrostatic repulsion between LsIA-R10 and K82 (Figure 8), which forms dramatically
enhanced interactions with LsIA#-C17. A previous study showed that the LsIA [R10F, N12L] facilitates
the selectivity of LsIA binding at human α3β4 over α7, Ls-AChBP and Ac-AChBP [27]. Thus, further
study may require the mutagenesis of LsIA#-R10, possibly substituted by hydrophobic residue,
for increasing the binding affinity of toxins at α3β2. Other studies also suggested the important role of
hydrophobic residues, such as alanine and leucine, at position 10 of toxins, for the augmented inhibition
of nAChRs by PnIA, PnIB and PeIA [S9H,V10A], respectively. A10 of PnIA and L10 of PnIB are
critical for the inhibitory effects by the peptides at α7, α3β4, and α3β4 nAChRs, respectively [34,63,64].
The replacement of alanine by leucine in position 10 of PnIA reduced the sensitivity to α3β2 [64].
Multiple amino acid substitutions, including position 10 of certain α-conotoxins, can also affect
the inhibition of nAChR subtypes. PeIA [S9H,V10A], for example, enhanced the selectivity of
the toxin to α3β2 and α6/α3β2β3 [65].
The findings in this computational study may provide data for further experimental study.
The in vitro cells, such as Xenopus laevis oocytes [34], human embryonic kidney (HEK-293) cells [66]
and SH-SY5Y cells [67], are widely applied in the functional characterization of nAChRs and their
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sensitivity to their potential antagonists (e.g. α-conotoxins and cocaine) [13,20,21,30,32,62,66,68,69],
namely, α3β2, α3β4, α7, α7β2, and AChBP for the crystallization of the structure. Among these cell
lines, the most commonly used cell is the Xenopus oocyte, which has been demonstrated to successfully
express different α3β4 and α9α10 nAChR stoichiometries [16,18].
4. Materials and Methods
In the present study, the complex ofα-conotoxin LsIA- and LsIA#-α3β2 nAChR was first established
via homology modelling with an appropriate template. The MD simulation was subsequently applied
for refining the comparative models and providing the trajectory, including the geometries, velocities
and energy of the atoms [70] for further analysis.
4.1. Homology Modelling
The comparative model of LsIA- and LsIA#-α3β2 nAChR complexes were built according to
the process described in our previous study [61]. Briefly, the sequence of LsIA bound to the extracellular
domain (ECD) of rat α3 subunit (UniProtKB-P04757) and rat β2 subunit (UniProtKB-P12390)
was aligned to that of α-conotoxin PnIA[A10K, D14K] bound to Aplysia californica acetylcholine
binding protein (Ac-AChBP) (PDB ID: 2BR8) [35], with the known crystal structure. The structure
with the best discrete optimized protein energy (DOPE) score was selected from 100 models built via
Modeller9v6 [42]. The DOPE score is calculated based on the distance-dependent energy function
applied in the homology modelling approach, Modeller, and is used to evaluate the homology models
at the atomic level [71]. The lower the DOPE, the better the model. The top view of the homology
model of the LsIA-bound α3β2 nAChR interfaces is shown in Figure 1A, whilst Figure 1B demonstrates
the side view of the motif of LsIA anchored to α3(+)β2(−) interface. The strategy, in which the model
was constructed for LsIA binding at five interfaces of α3β2 nAChR, was also widely employed in other
studies on α-conotoxin bound heteropentameric nAChR complexes [20,27,72]. It should be noted that
the commonly assumed order of (α3)2(β2)3 for the homology modelling of the nicotinic receptor is
α3−β2−α3−β2−β2 [19,24]. Although there is a lack of studies of concatemeric constructs of α3β2
nAChR, classic concatemer studies of α4β2 by Carbone et al. [73] indicated that functional receptor
assemblies do not involve triplets of the same subunit. Thus, the αβαββ assembly motif is assumed to
constitute the functional form of (α3)2(β2)3 as well.
As in our previous study on LsIA-α7 complexes [23], we noted that a recent co-crystal structure is
available of Ls-AChBP, bound to amidated α-conotoxin LsIA (PDB code: 5T90 [29]), which showed
minor structural differences in AChBP compared to all other conotoxin-Ac-AChBP crystal structures
to date, possibly due to species differences between Ls- and Ac-AChBP. The authors constructed
homology models of LsIA bound to α7 nAChR or apo α7 nAChR based on the Ls-AChBP crystal
structure, and comprehensively elaborated and tested key interactions identified in the model
in many elegant experiments [27,74]. In both cases, minor structural differences between Ls-
and Ac-AChBP, and the availability of co-crystal structures of 4/7-conotoxins bound to both species
isoforms, allow the exploration of an alternative, possible conformation of LsIA-α3β2 complex based
on Ac-AChBP, which shares a comparable (though somewhat lower) sequence similarity to rat α3
and β2 subunits.
In addition, the recently revealed X-ray structure of human α4β2 nAChR co-crystallized with
nicotine (PDB ID:5KXI) [75] putatively supports the homology modelling of (α4)3(β2)2 nAChR
stoichiometry [76] and molecular docking studies on α4β2 nAChR [77–79] for the small molecules,
such as nicotine. Additionally, this determined structure companied with the complex of Ac-AChBP
co-crystallized with the PnIA variant, benefits the comparative modelling of (α3)3(β4)2 and (α3)2(β4)3
nAChRs bound by α-conotoxin AuIB [15]. However, the nicotine bound α4β2 nAChR (PDB ID:
5KXI) [75] was only used for the construction of (α3)3(β4)2/ribbon isomer of AuIB (linking cysteine
residues I-IV, II-III) complex [15], whereas the globular AuIB (linking cysteine residues I-III, II-IV)
anchoring to (α3)2(β4)3 was based on the same template (PDB ID: 2BR8) [35] as in the present study.
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4.2. Molecular Dynamics Simulation
4.2.1. MD Simulations on LsIA-α3β2 Complexes
MD simulations were carried out on the complexes using GROMACS 4.6.5 [43]
and the CHARMM27 force field. The refined protein complexes were analyzed by following the process
described previously [61]. To improve conformational sampling, each LsIA-α3β2 complex was run
using 28 independent simulations, each initiated using a different random seed, up to at least
27ns. Unless otherwise stated, all subsequent results are reported as averages over the independent
trajectories. Both systems were solvated with TIP3P water models [80]. For the LsIA-α3β2 complex,
70 mM Cl− and 110 mM Na+ were added, to achieve an approximately 0.15 M salt concentration,
whereas for the LsIA#-α3β2 complex, 70 Cl− and 115 Na+ ions were added. Simulation trajectory
frames were recorded every 10 ps for data analysis. The inter-subunit contacts were visualized through
Cytoscape [57], which was also performed in our previous study [23]. All structure graphics were
generated via visual molecular dynamics (VMD) [81]. Other simulation conditions and parameters
are the same as those applied in our previous study [55]. The cluster analyses were performed over
the whole trajectories for both LsIA and LsIA# bound forms via GROMACS packages. The trajectory
frame interval was extracted every 10 frames, therefore around 7634 frames were acquired for clustering.
The cutoff for LsIA- and LsIA#-α3β2 complexes was set up as 0.38 Å. As a result, the number of
identified clusters for LsIA and LsIA# bound forms was 8 and 10, respectively. The top 1 ranked
conformations (top 1 cluster) represent 92.4% (LsIA) and 91.4% (LsIA#) for the overall structural
population for each protein complex, and were selected for APBS analysis [50] in the PyMOL APBS
plugin [51] (APBS Tools 2.1).
4.2.2. MD Simulations on LsIA Only
To compare the intramolecular interactions within the LsIA/LsIA# in solution with their
nAChR-bound forms, simulations were deployed only on LsIA and LsIA#, respectively, for 300 ns
each. Consistent with the simulations on the receptor-ligand complexes, the result showed a proximate
distance between R10 and C17 of LsIA# (3.44 Å ± 1.4) versus that of the LsIA (3.38 Å ± 0.96).
For achieving 0.15 M concentration, the LsIA and LsIA# were solvated with 3 mM Na+ and 5 mM
Cl−, and 3 mM Na+ and 4 mM Cl−, respectively, as well as water molecule models (TIP3P). The other
parameters for simulation in this step are consistent with those for LsIA-α3β2 complex simulations.
5. Conclusions
In the present study, we built molecular models of α3β2 nAChR bound by LsIA and LsIA# for an
investigation of the effects of the C-terminal carboxylation of LsIA on the receptor interactions versus
the wild type LsIA. The findings may provide new insights into elucidating the effects of different
α3β2 binding interfaces, mainly between α3(+)β2(−) and β2(+)α3(−) interfaces, on the interactions by
the LsIA and the residues on α3β2 nAChR.
An examination of the RMSD plots of LsIA at the α3(+)β2(−), β2(+)α3(−) and β2(+)β2(−)
interfaces suggests that the toxins adopt remarkably different conformations at the latter interface,
possibly indicating that the β2(+)β2(−) is unsuited to facilitate LsIA binding and inhibition. Subsequent
discussions were, therefore, largely focused on the mixed-subunit interfaces. At both α3(+)β2(−)
and β2(+)α3(−) interfaces, the carboxylated C-T (C17) forms strong hydrogen bonds/salt bridges
with lysines at position 187 (at α3(+)β2(−) interfaces) and 82 (at β2(+)α3(−) interfaces), which occur
together with the significantly enhanced interactions by P14 and P7 with hydrophobic residues (L145,
W81 and F143) on the (−) face of α3(+)β2(−) interfaces. In addition, homologous residues, leucine
and isoleucine, at positions 145 and 144 of β2(−) and α3(−) subunits, respectively, may contribute to
the enhanced binding affinity of LsIA# at both interfaces via forming van der Waals interactions with
LsIA#-R10. However, at β2(+)α3(−) interfaces, only LsIA#-V11 was observed to establish markedly
augmented hydrophobic contacts with α3(−)-L134, compromised by the reduced hydrophobic contacts
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between LsIA#-P7 and α3(−)-W80. On the (+) face, β2(+)-Y215 exhibits enhanced hydrogen bond
contacts with C3 of LsIA# versus the LsIA bound form at α3(+)β2(−) binding sites. By contrast,
the significantly reduced contacts, for LsIA#, between β2(+)-Y177 and N12 at β2(+)β2(−) interfaces,
decreased the total number of receptor contacts by LsIA#.
Combined with the enhanced rigidity of the residues (from position 13 to 17) of LsIA#
over LsIA, we propose that the significant changes due to C-terminal carboxylation may occur
predominantly at α3(+)β2(−) and β2(+)α3(−) interfaces, rather than β2(+)β2(−) sites, via hydrophobic
and salt-bridge/hydrogen bond interactions at complementary faces.
The determinants predicted in this study may provide information for the improvement of
selectivity and specificity of LsIA to the nAChRs. Experimental studies employing the mutagenesis
or synthesis of chemically modified α-conotoxins may be conducted in the future to improve
the effectiveness of mediating nicotinic receptor activity as molecular drugs for novel therapies
with fewer side effects.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/18/7/349/s1.
Figure S1: RMS Fluctuation (RMSF) plots of α-conotoxin LsIA/LsIA# binding at α3β2 nAChR; Figure S2:
Convergence study via calculating the sum of squared differences (SSD) between 3, 6, 9, 15, 18, 21, 24 and 27 ns
RMSFs with the 27 ns simulations; Figure S3: Significant changes of pairwise contacts for LsIA anchoring to
β2(+)β2(−) interface of α3β2 nAChR; Figure S4: The α3β2 nAChR interface interactions with LsIA and LsIA#,
respectively, according to the statistically significant variations of receptor contacts by C-terminal carboxylation;
Figure S5: Intra-molecular contacts between R10 and C17 of LsIA# versus LsIA binding at α3(+)β2(−) interfaces;
Figure S6. Interactions formed by LsIA-G2 and C3 with the receptor residues on the principal (+) face at α3(+)β2(−)
interface of α3β2 nAChR; Figure S7: Interactions formed by LsIA-P7 and C9 with the receptor residues on
the principal (+) face at α3(+)β2(−) interface; Figure S8: Interactions formed by LsIA-P7 and A8 with the receptor
residues on the principal (+) face at β2(+)α3(−) interface of α3β2 nAChR; Figure S9: Important interactions
formed by LsIA-C9 and N12 with the relative residues on β2(+)β2(−) interface of α3β2 nAChR; Figure S10:
The distance of the inter-subunit interactions between the principal (+) and the accessory (−) face of α3β2 nAChR
interfaces bound by LsIAs. The trajectory data is available at the Zenodo repository (DOI: 10.5281/zenodo.3908769).
Author Contributions: The authors’ contributions in this study are listed as follows. Conceptualization, J.W.
and A.H.; methodology, J.W. and A.H.; visualization, J.W. and A.H; writing—original draft preparation, J.W.;
writing—review and editing D.J.A., A.H. and J.W., supervision, D.J.A. and A.H.; funding acquisition, D.J.A.
and A.H. All authors have read and agreed to the published version of the manuscript.
Funding: This work is funded by The Australian Research Council Discovery Project, grant DP150103990.
Acknowledgments: The authors appreciate Quentin Kaas (University of Queensland, Australia), Han-Shen
Tae (University of Wollongong, Australia) and Associate Professor Rilei Yu (Ocean University of China)
for their helpful feedback on this manuscript. The computational resource was provided by the National
Computational Infrastructure (NCI) and the Pawsey Supercomputing Centre (Australia), and CSCS Swiss National
Supercomputing Centre (Switzerland) via the PRACE Project Access scheme.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ellison, M.; Gao, F.; Wang, H.-L.; Sine, S.M.; McIntosh, J.M.; Olivera, B.M. α-Conotoxins ImI and ImII target
distinct regions of the human α7 nicotinic acetylcholine receptor and distinguish human nicotinic receptor
subtypes. Biochemistry 2004, 43, 16019–16026. [CrossRef] [PubMed]
2. Gotti, C.; Moretti, M.; Bohr, I.; Ziabreva, I.; Vailati, S.; Longhi, R.; Riganti, L.; Gaimarri, A.; McKeith, I.G.;
Perry, R.H.; et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer´s disease,
Parkinson´s disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis. 2006, 23,
481–489. [CrossRef] [PubMed]
3. Hurst, R.; Rollema, H.; Bertrand, D. Nicotinic acetylcholine receptors: From basic science to therapeutics.
Pharmacol. Therapeut. 2013, 137, 22–54. [CrossRef] [PubMed]
4. Dineley, K.T.; Pandya, A.A.; Yakel, J.L. Nicotinic ACh receptors as therapeutic targets in CNS disorders.
Trends Pharmacol. Sci. 2015, 36, 96–108. [CrossRef]
5. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61, 75–111.
[CrossRef]
Mar. Drugs 2020, 18, 349 20 of 23
6. Everhart, D.; Cartier, G.E.; Malhotra, A.; Gomes, A.V.; McIntosh, J.M.; Luetje, C.W. Determinants of potency
on α-conotoxin MII, a peptide antagonist of neuronal nicotinic receptors. Biochemistry 2004, 43, 2732–2737.
[CrossRef]
7. McIntosh, J.M.; Azam, L.; Staheli, S.; Dowell, C.; Lindstrom, J.M.; Kuryatov, A.; Garrett, J.E.; Marks, M.J.;
Whiteaker, P. Analogs of α-conotoxin MII are selective for α6-containing nicotinic acetylcholine receptors.
Mol. Pharmacol. 2004, 65, 944–952. [CrossRef]
8. Gao, F.; Mer, G.; Tonelli, M.; Hansen, S.B.; Burghardt, T.P.; Taylor, P.; Sine, S.M. Solution NMR of acetylcholine
binding protein reveals agonist-mediated conformational change of the C-loop. Mol. Pharmacol. 2006, 70,
1230–1235. [CrossRef]
9. Inserra, M.C.; Kompella, S.N.; Vetter, I.; Brust, A.; Daly, N.L.; Cuny, H.; Craik, D.J.; Alewood, P.F.; Adams, D.J.;
Lewis, R.J. Isolation and characterization of α-conotoxin LsIA with potent activity at nicotinic acetylcholine
receptors. Biochem. Pharmacol. 2013, 86, 791–799. [CrossRef]
10. Cox, B.C.; Marritt, A.M.; Perry, D.C.; Kellar, K.J. Transport of multiple nicotinic acetylcholine receptors
in the rat optic nerve: High densities of receptors containing α6 and β3 subunits. J. Neurochem. 2008, 105,
1924–1938. [CrossRef]
11. Millar, N.S.; Gotti, C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56,
237–246. [CrossRef] [PubMed]
12. Miles, T.F.; Dougherty, D.A.; Lester, H.A. The 5-HT3AB receptor shows an A3B2 stoichiometry at the plasma
membrane. Biophys. J. 2013, 105, 887–898. [CrossRef] [PubMed]
13. Lamotte d´Incamps, B.; Zorbaz, T.; Dingova, D.; Krejci, E.; Ascher, P. Stoichiometry of the heteromeric
nicotinic receptors of the Renshaw cell. J. Neurosci. Res. 2018, 38, 4943–4956. [CrossRef] [PubMed]
14. Moroni, M.; Bermudez, I. Stoichiometry and pharmacology of two human α4β2 nicotinic receptor types.
J. Mol. Neurosci. 2006, 30, 95–96. [CrossRef]
15. Wu, X.; Tae, H.-S.; Huang, Y.-H.; Adams, D.J.; Craik, D.J.; Kaas, Q. Stoichiometry dependent inhibition of rat
α3β4 nicotinic acetylcholine receptor by the ribbon isomer of α-conotoxin AuIB. Biochem. Pharmacol. 2018,
155, 288–297. [CrossRef]
16. Mazzaferro, S.; Benallegue, N.; Carbone, A.; Gasparri, F.; Vijayan, R.; Biggin, P.C.; Moroni, M.; Bermudez, I.
Additional acetylcholine (ACh) binding site at α4/α4 interface of (α4β2) 2α4 nicotinic receptor influences
agonist sensitivity. J. Biol. Chem. 2011, 286, 31043–31054. [CrossRef]
17. Harpsøe, K.; Ahring, P.K.; Christensen, J.K.; Jensen, M.L.; Peters, D.; Balle, T. Unraveling the high-
and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J. Neurosci. Res. 2011, 31,
10759–10766. [CrossRef]
18. Boffi, J.C.; Marcovich, I.; Gill-Thind, J.K.; Corradi, J.; Collins, T.; Lipovsek, M.M.; Moglie, M.; Plazas, P.V.;
Craig, P.O.; Millar, N.S.; et al. Differential contribution of subunit interfaces to α9α10 nicotinic acetylcholine
receptor function. Mol. Pharmacol. 2017, 91, 250–262. [CrossRef]
19. Indurthi, D.C.; Pera, E.; Kim, H.-L.; Chu, C.; McLeod, M.D.; McIntosh, J.M.; Absalom, N.L.; Chebib, M.
Presence of multiple binding sites on α9α10 nAChR receptors alludes to stoichiometric-dependent action of
the α-conotoxin, Vc1.1. Biochem. Pharmacol. 2014, 89, 131–140. [CrossRef]
20. Sambasivarao, S.V.; Roberts, J.; Bharadwaj, V.S.; Slingsby, J.G.; Rohleder, C.; Mallory, C.; Groome, J.R.;
McDougal, O.M.; Maupin, C.M. Acetylcholine promotes binding of α-Conotoxin MII at α3β2 nicotinic
acetylcholine receptors. ChemBioChem 2014, 15, 413–424. [CrossRef]
21. Dutertre, S.; Nicke, A.; Lewis, R.J. β2 subunit contribution to 4/7 α-conotoxin binding to the nicotinic
acetylcholine receptor. J. Biol. Chem. 2005, 280, 30460–30468. [CrossRef] [PubMed]
22. Shiembob, D.L.; Roberts, R.L.; Luetje, C.W.; McIntosh, J.M. Determinants of α-conotoxin BuIA selectivity on
the nicotinic acetylcholine receptor β subunit. Biochemistry 2006, 45, 11200–11207. [CrossRef] [PubMed]
23. Zhangsun, D.; Zhu, X.; Wu, Y.; Hu, Y.; Kaas, Q.; Craik, D.J.; McIntosh, J.M.; Luo, S. Key residues in the nicotinic
acetylcholine receptor β2 subunit contribute to α-conotoxin LvIA binding. J. Biol. Chem. 2015, 290, 9855–9862.
[CrossRef] [PubMed]
24. Walsh, R.M., Jr.; Roh, S.-H.; Gharpure, A.; Morales-Perez, C.L.; Teng, J.; Hibbs, R.E. Structural principles of
distinct assemblies of the human α4β2 nicotinic receptor. Nature 2018, 557, 261–265. [CrossRef]
25. Di Cesare Mannelli, L.; Cinci, L.; Micheli, L.; Zanardelli, M.; Pacini, A.; McIntosh, J.M.; Ghelardini, C.
α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both
neuronal and glial derangement. Pain 2014, 155, 1986–1995. [CrossRef]
Mar. Drugs 2020, 18, 349 21 of 23
26. Nicke, A.; Loughnan, M.L.; Millard, E.L.; Alewood, P.F.; Adams, D.J.; Daly, N.L.; Craik, D.J.; Lewis, R.J.
Isolation, structure, and activity of GID, a novel α4/7-conotoxin with an extended N-terminal sequence.
J. Biol. Chem. 2003, 278, 3137–3144. [CrossRef]
27. Abraham, N.; Healy, M.; Ragnarsson, L.; Brust, A.; Alewood, P.F.; Lewis, R.J. Structural mechanisms for
α-conotoxin activity at the human α3β4 nicotinic acetylcholine receptor. Sci. Rep. 2017, 7, 45466. [CrossRef]
28. Loughnan, M.L.; Nicke, A.; Jones, A.; Adams, D.J.; Alewood, P.F.; Lewis, R.J. Chemical and functional
identification and characterization of novel sulfated α-conotoxins from the cone snail Conus anemone. J. Med.
Chem. 2004, 47, 1234–1241. [CrossRef]
29. Armishaw, C.J. Synthetic α-conotoxin mutants as probes for studying nicotinic acetylcholine receptors
and in the development of novel drug leads. Toxins 2010, 2, 1471. [CrossRef]
30. Cartier, G.E.; Yoshikami, D.; Gray, W.R.; Luo, S.; Olivera, B.M.; McIntosh, J.M. A new α-conotoxin which
targets α3β2 nicotinic acetylcholine receptors. J. Biol. Chem. 1996, 271, 7522–7528. [CrossRef]
31. Dutertre, S.; Nicke, A.; Tyndall, J.D.A.; Lewis, R.J. Determination of α-conotoxin binding modes on neuronal
nicotinic acetylcholine receptors. J. Mol. Recognit. 2004, 17, 339–347. [CrossRef] [PubMed]
32. Luo, S.; Akondi, K.B.; Zhangsun, D.; Wu, Y.; Zhu, X.; Hu, Y.; Christensen, S.; Dowell, C.; Daly, N.L.; Craik, D.J.;
et al. Atypical α-conotoxin LtIA from Conus Litteratus targets a novel microsite of the α3β2 nicotinic receptor.
J. Biol. Chem. 2010, 285, 12355–12366. [CrossRef] [PubMed]
33. Dellisanti, C.D.; Yao, Y.; Stroud, J.C.; Wang, Z.-Z.; Chen, L. Crystal structure of the extracellular domain of
nAChR α1 bound to α-bungarotoxin at 1.94 Å resolution. Nat. Neurosci. 2007, 10, 953. [CrossRef] [PubMed]
34. Dutertre, S.; Ulens, C.; Büttner, R.; Fish, A.; van Elk, R.; Kendel, Y.; Hopping, G.; Alewood, P.F.; Schroeder, C.;
Nicke, A.; et al. AChBP-targeted α-conotoxin correlates distinct binding orientations with nAChR subtype
selectivity. EMBO J. 2007, 26, 3858–3867. [CrossRef]
35. Celie, P.H.N.; Kasheverov, I.E.; Mordventisev, D.Y.; Hogg, R.C.; van Nierop, P.; van Elk, R.; van
Rossum-Fikkert, S.E.; Zhmak, M.N.; Bertrand, D.; Tsetlin, V.; et al. Crystal structure of nicotinic acetylcholine
receptor homolog AChBP in complex with an α-conotoxin PnIA variant. Nat. Struct. Mol. Biol. 2005, 12,
582–588. [CrossRef]
36. Grishin, A.A.; Cuny, H.; Hung, A.; Clark, R.J.; Brust, A.; Akondi, K.; Alewood, P.F.; Craik, D.J.; Adams, D.J.
Identifying key amino acid residues that affect α-conotoxin AuIB inhibition of α3β4 nicotinic acetylcholine
receptors. J. Biol. Chem. 2013, 288, 34428–34442. [CrossRef]
37. Suresh, A.; Hung, A. Molecular simulation study of the unbinding of α-conotoxin [Υ4E]GID at the α7
and α4β2 neuronal nicotinic acetylcholine receptors. J. Mol. Graph. Model. 2016, 70, 109–121. [CrossRef]
38. Xu, M.; Zhu, X.; Yu, J.; Yu, J.; Luo, S.; Wang, X. The crystal structure of Ac-AChBP in complex with
α-conotoxin LvIA reveals the mechanism of its selectivity towards different nAChR subtypes. Protein Cell
2017. [CrossRef]
39. Ulens, C.; Hogg, R.C.; Celie, P.H.; Bertrand, D.; Tsetlin, V.; Smit, A.B.; Sixma, T.K. Structural determinants of
selective α-conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. Proc. Natl. Acad. Sci.
USA 2006, 103, 3615–3620. [CrossRef]
40. Zouridakis, M.; Papakyriakou, A.; Ivanov, I.A.; Kasheverov, I.E.; Tsetlin, V.; Tzartos, S.; Giastas, P.
Crystal structure of the monomeric extracellular domain of α9 nicotinic receptor subunit in complex
with α-conotoxin RgIA: Molecular dynamics insights into RgIA binding to α9α10 nicotinic receptors.
Front. Pharmacol. 2019, 10. [CrossRef]
41. Bourne, Y.; Talley, T.T.; Hansen, S.B.; Palmer, T.; Marchot, P. Crystal structure of a Cbtx-AChBP complex
reveals essential interactions between snake α-neurotoxins and nicotinic receptors. EMBO J. 2005, 24,
1512–1522. [CrossRef] [PubMed]
42. Eswar, N.; Webb, B.; Marti-Renom, M.A.; Madhusudhan, M.S.; Eramian, D.; Shen, M.-Y.; Pieper, U.; Sali, A.
Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinform. 2006. [CrossRef] [PubMed]
43. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: Algorithms for highly efficient,
load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 2008, 4, 435–447. [CrossRef]
[PubMed]
44. Kufareva, I.; Abagyan, R. Methods of protein structure comparison. Methods Mol. Biol. 2012, 857, 231–257.
[CrossRef]
Mar. Drugs 2020, 18, 349 22 of 23
45. Yi, M.; Tjong, H.; Zhou, H.-X. Spontaneous conformational change and toxin binding in α7 acetylcholine
receptor: Insight into channel activation and inhibition. Proc. Natl. Acad. Sci. USA 2008, 105, 8280–8285.
[CrossRef]
46. Yu, R.; Craik, D.J.; Kaas, Q. Blockade of neuronal α7-nAChR by α-conotoxin ImI explained by computational
scanning and energy calculations. PLoS Comput. Biol. 2011, 7, e1002011. [CrossRef]
47. Sahu, B.S.; Obbineni, J.M.; Sahu, G.; Singh, P.K.; Sonawane, P.J.; Sasi, B.K.; Allu, P.K.R.; Maji, S.K.; Bera, A.K.;
Senapati, S.; et al. Molecular interactions of the physiological anti-hypertensive peptide catestatin with
the neuronal nicotinic acetylcholine receptor. J. Cell Sci. 2012, 125, 2323–2337. [CrossRef]
48. Dong, Y.-W.; Liao, M.-L.; Meng, X.-L.; Somero, G.N. Structural flexibility and protein adaptation to
temperature: Molecular dynamics analysis of malate dehydrogenases of marine molluscs. Proc. Natl. Acad.
Sci. USA 2018, 115, 1274–1279. [CrossRef]
49. Meher, B.R.; Wang, Y. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor
TMC114: Flap dynamics and binding mechanism. J. Mol. Graph. Model. 2015, 56, 60–73. [CrossRef]
50. Baker, N.A.; Sept, D.; Joseph, S.; Holst, M.J.; McCammon, J.A. Electrostatics of nanosystems: Application to
microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 2001, 98, 10037–10041. [CrossRef]
51. Lerner, M.; Carlson, H. APBS Plugin for PyMOL. University of Michigan. Ann. Arbor. 2006, 7, 14.
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